Clinical Trial Update: Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib [Phase 2]

View source ↗

Summary

Phase 2 study comparing temsirolimus and sunitinib in non-clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• Torisel (Temsirolimus)

Snippet

Sponsor: Central European Society for Anticancer Drug Research | Conditions: Non-clear Cell Renal Cell Cancer | Phase 2 | Status: COMPLETED